[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2080745T3 - Agentes citotoxicos de longitud de onda especifica - Google Patents

Agentes citotoxicos de longitud de onda especifica

Info

Publication number
ES2080745T3
ES2080745T3 ES89307281T ES89307281T ES2080745T3 ES 2080745 T3 ES2080745 T3 ES 2080745T3 ES 89307281 T ES89307281 T ES 89307281T ES 89307281 T ES89307281 T ES 89307281T ES 2080745 T3 ES2080745 T3 ES 2080745T3
Authority
ES
Spain
Prior art keywords
tissues
specific
cells
wave length
cytotoxic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89307281T
Other languages
English (en)
Inventor
Julia G Levy
David Dolphin
Jack K Chow
Ethan Sternberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of ES2080745T3 publication Critical patent/ES2080745T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

UN GRUPO DE HIDRO-MONOBENZOPORFIRINAS "PORFIRINAS VERDES" (GP), QUE TIENEN MAXIMOS DE ABSORCION EN EL INTERVALO DE 670-780 NM ES UTIL PARA TRATAR DESORDENES O CONDICIONES QUE ESTAN SOMETIDAS A TRATAMIENTO DERIVATIVO DE HEMATOPORFIRINA (HPD) EN PRESENCIA DE LUZ, O PARA TRATAR VIRUS, CELULAS Y TEJIDOS, GENERALMENTE PARA DESTRUIR BLANCOS NO DESEADOS. EL USO DE LA GP DE LA INVENCION PERMITE LA IRRADIACION USANDO LONGITUDES DE ONDA DISTINTAS DE LAS ABSORBIDAS POR LA SANGRE. LA GP DE LA INVENCION TAMBIEN SE PUEDE CONJUGAR A LIGANDOS ESPECIFICOS PARA EL RECEPTOR O A INMUNOGLOBULINAS ESPECIFICAS, O SUS FRAGMENTOS, PARA HACER COMO BLANCO AL TRATAMIENTO CON LA RADIACION DE TEJIDOS O CELULAS ESPECIFICOS. EL USO DE ESTOS MATERIALES PERMITE UTILIZAR NIVELES BAJOS DE MEDICAMENTO, EVITANDO ASI REACCIONES SECUNDARIAS QUE PUEDEN DESTRUIR LOS TEJIDOS NORMALES.
ES89307281T 1988-07-19 1989-07-19 Agentes citotoxicos de longitud de onda especifica Expired - Lifetime ES2080745T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/221,161 US4920143A (en) 1987-04-23 1988-07-19 Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents

Publications (1)

Publication Number Publication Date
ES2080745T3 true ES2080745T3 (es) 1996-02-16

Family

ID=22826617

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94115192T Expired - Lifetime ES2169060T3 (es) 1988-07-19 1989-07-19 Agentes citotoxicos de longitud de onda especifica.
ES89307281T Expired - Lifetime ES2080745T3 (es) 1988-07-19 1989-07-19 Agentes citotoxicos de longitud de onda especifica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94115192T Expired - Lifetime ES2169060T3 (es) 1988-07-19 1989-07-19 Agentes citotoxicos de longitud de onda especifica.

Country Status (10)

Country Link
US (1) US4920143A (es)
EP (2) EP0352076B1 (es)
AT (2) ATE209650T1 (es)
AU (1) AU638675B2 (es)
CA (1) CA1339927C (es)
DE (3) DE68924215T2 (es)
ES (2) ES2169060T3 (es)
GR (1) GR3017426T3 (es)
LU (1) LU90718I2 (es)
NL (1) NL300037I2 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
USRE38994E1 (en) 1988-07-20 2006-02-28 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5198460A (en) * 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
USRE39094E1 (en) * 1988-07-20 2006-05-09 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
WO1990015059A1 (en) * 1989-06-07 1990-12-13 The University Of British Columbia Photosensitizing diels-alder porphyrin derivatives
US5087636A (en) * 1990-02-20 1992-02-11 University Of British Columbia Method to destroy malignant cells in mononuclear cell populations
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
GB9014307D0 (en) * 1990-06-27 1990-08-15 Scient Generics Ltd Method of treatment and compositions therefor
US5219878A (en) * 1990-10-05 1993-06-15 Queen's University Tetrapyrrole hydroxyalkylamide photochemotherapeutic agents
US5435307A (en) * 1991-03-29 1995-07-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Surface fluorescent monitor
CA2087902C (en) * 1992-02-05 2006-10-17 Narendra Raghunathji Desai Liposome compositions of porphyrin photosensitizers
US6890555B1 (en) * 1992-02-05 2005-05-10 Qlt, Inc. Liposome compositions of porphyrin photosensitizers
US5330741A (en) * 1992-02-24 1994-07-19 The Regents Of The University Of California Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors
CA2097280A1 (en) * 1992-06-01 1993-12-02 Sandor G. Vari Apparatus and method of use for a photosensitizer enhanced fluorescence based bipsy needle
AU4695493A (en) * 1992-08-17 1994-03-15 Quadra Logic Technologies Inc. Method for destroying or inhibiting growth of unwanted cells or tissues
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
ITFI940095A1 (it) * 1994-05-23 1995-11-23 Molteni & C Coniugati fotodinamici aventi proprieta' biocide
US5882328A (en) * 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
US6096776A (en) * 1995-01-17 2000-08-01 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US6107325A (en) * 1995-01-17 2000-08-22 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
DE19514088A1 (de) 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen
US5707608A (en) * 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
WO1997026885A1 (en) * 1996-01-23 1997-07-31 The General Hospital Corporation Doing Business As Massachusetts General Hospital Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
WO1999013943A1 (en) 1996-03-05 1999-03-25 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5693789A (en) * 1996-04-10 1997-12-02 Abbott Laboratories Process for the preparation of a protoporphyrin
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
US6043237A (en) * 1996-12-10 2000-03-28 Qlt Phototherapeutics, Inc. Use of photodynamic therapy for prevention of secondary cataracts
EP0983273B8 (en) * 1997-05-07 2002-10-09 QLT Inc. Ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents
US5880145A (en) * 1997-05-07 1999-03-09 The University Of British Columbia Class of benzoporphyrin derivative photoactive compounds
US6756396B1 (en) * 1997-05-07 2004-06-29 Qlt Inc. Ethylene glycol esters as photoactive agents
ATE253068T1 (de) * 1997-05-07 2003-11-15 Univ British Columbia Ein klasse von benzoporphyrin derivate photowirksame verbindungen
WO1999004857A1 (de) 1997-07-28 1999-02-04 Novartis Ag Vorrichtung und verfahren zum bestrahlen eines auges eines patienten für eine photodynamische therapie
CA2221912A1 (en) * 1997-11-21 1999-05-21 David Dolphin Photosensitizers with improved biodistribution and light-absorbing properties
US6316215B1 (en) 1999-12-27 2001-11-13 Edwin L. Adair Methods of cancer screening utilizing fluorescence detection techniques and selectable imager charge integration periods
EP1045704B1 (en) 1998-01-06 2004-09-22 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
WO2000061585A2 (en) 1999-04-14 2000-10-19 The University Of British Columbia (Ubc) 1,3-dipolar cycloadditions to polypyrrolic macrocycles
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US7122568B1 (en) 1999-11-17 2006-10-17 Qlt, Inc. Use of low-dose PDT to inhibit restenosis
US6750037B2 (en) 1999-12-27 2004-06-15 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6984498B2 (en) * 1999-12-27 2006-01-10 Adair Edwin L Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6190877B1 (en) 1999-12-27 2001-02-20 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques
BR0109499A (pt) * 2000-03-24 2002-12-10 Novartis Ag Tratamento melhorado de neovascularização
US7282215B2 (en) 2000-05-08 2007-10-16 The University Of British Columbia Supports for photosensitizer formulations
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US20030103995A1 (en) 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
CA2466103C (en) * 2001-11-02 2010-06-15 The Governors Of The University Of Alberta Micelle compositions containing pegylated phospholipids and a photosensitizer
NZ533036A (en) * 2001-11-09 2006-04-28 Quadra Logic Tech Inc Compositions comprising a photosensitizer and skin penetration enhancer and their use in photodynamic treatment for alopecia cancer acne psoriasis dermatitis ablation and promoting hair growth
EP1374912B1 (en) * 2002-06-21 2006-08-16 Edwin L. Adair Use of metaloporphyrins for treatment of arteriosclerotic lesions
AU2003301267A1 (en) * 2002-10-18 2004-05-04 The Regents Of The University Of California Photodynamic therapy for ocular neovascularization
US20040220167A1 (en) * 2003-05-02 2004-11-04 Nasrollah Samiy Methods of treating neuralgic pain
CA2437638A1 (en) * 2003-08-20 2005-02-20 John Robert North Photodynamic therapy
CA2457214A1 (en) 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
AU2005302256B2 (en) 2004-10-29 2011-01-20 Cerus Corporation Improved quenching methods for red blood cell inactivation process
KR101742533B1 (ko) 2008-04-09 2017-06-01 세루스 코포레이션 적혈구 병원체 불활성화를 위한 개선된 퀀칭 방법
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
BR112013017953A2 (pt) 2011-01-13 2017-08-29 Quadra Logic Tech Inc Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
SG11201405553YA (en) 2012-03-08 2014-11-27 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
BR112015000383A2 (pt) 2012-07-11 2017-06-27 Dermira Inc composição farmacêutica, e, métodos para preparação de uma composição farmacêutica, para reduzir a taxa de excreção de sebo das glândulas sebáceas na pele de um indivíduo e para tratamento da acne
JP6282745B2 (ja) 2013-09-12 2018-02-21 ハロザイム インコーポレイテッド 修飾抗上皮成長因子受容体抗体およびその使用法
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
MA47786A (fr) 2017-03-14 2020-01-22 Ohio State Innovation Foundation Méthodes et compositions se rapportant à des immunoconjugués igg3 ciblant le facteur tissulaire
CN112204048A (zh) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 抗cct5结合分子及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2951800A (en) * 1957-11-13 1960-09-06 Monsanto Chemicals Photoxidation processes utilizing improved catalysts
WO1984001382A1 (en) * 1982-09-27 1984-04-12 Oncology Research & Dev Inc Purified hematoporphyrin derivative for diagnosis and treatment of tumors, and method
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4675338A (en) * 1984-07-18 1987-06-23 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
AU583854B2 (en) * 1984-09-13 1989-05-11 Cytogen Corporation Antibody therapeutic agent conjugates
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents

Also Published As

Publication number Publication date
DE10199008I2 (de) 2004-10-14
EP0352076A2 (en) 1990-01-24
US4920143A (en) 1990-04-24
CA1339927C (en) 1998-06-23
DE10199008I1 (de) 2003-06-12
ATE127696T1 (de) 1995-09-15
EP0352076A3 (en) 1991-07-17
DE68929351D1 (de) 2002-01-10
NL300037I1 (nl) 2001-03-01
GR3017426T3 (en) 1995-12-31
AU3825889A (en) 1990-02-08
EP0641796A1 (en) 1995-03-08
DE68929351T2 (de) 2002-05-08
EP0641796B1 (en) 2001-11-28
NL300037I2 (nl) 2001-08-01
EP0352076B1 (en) 1995-09-13
DE68924215D1 (de) 1995-10-19
ES2169060T3 (es) 2002-07-01
ATE209650T1 (de) 2001-12-15
LU90718I2 (fr) 2001-03-01
DE68924215T2 (de) 1996-02-15
AU638675B2 (en) 1993-07-08

Similar Documents

Publication Publication Date Title
ES2169060T3 (es) Agentes citotoxicos de longitud de onda especifica.
Fingar et al. Drug and light dose dependence of photodynamic therapy: a study of tumor and normal tissue response
Bown et al. Photodynamic therapy with porphyrin and phthalocyanine sensitisation: quantitative studies in normal rat liver
Benson Jr et al. Treatment of transitional cell carcinoma of the bladder with hematoporphyrin derivative phototherapy
JP4662631B2 (ja) 光エネルギを用いた色素沈着組織の治療装置
US5913884A (en) Inhibition of fibrosis by photodynamic therapy
EP0947222B1 (en) Method of activating photosensitive agents
US20050004510A1 (en) Noninvasive vascular therapy
ES2055735T3 (es) Agentes citotoxicos con longitud de onda especifica.
BR9712599A (pt) Processos para o tratamento de um volume particular, de câncer e de um volume de tecido canceroso em tecido e para produzir pelo menos um agente molecular foto-ativo num volume particular de material e aparelhos para o tratamento de um volume particular de tecido de planta ou de animal e para a administração de um tratamento médico foto-dinâmico
KR20010083045A (ko) 치료제의 다광자 광활성화를 위한 개선된 방법 및 장치
EP0425566A4 (en) New photosensitizing agents
Wachter et al. Simultaneous two-photon excitation of photodynamic therapy agents
PT933995E (pt) Metodo para tratamento de lesao endotelial
EP1120119A4 (en) REMEDIES FOR PHOTOCHEMOTHERAPY
WO2000041725A3 (en) Therapeutic compositions for metabolic bone disorders or bone metastases
WO1992000106A3 (en) Method of treatment and compositions therefore
PT1267931E (pt) Derivados de rodamina para o diagnostico e tratamento fotodinamicos
Mimura et al. Cooperative Clinical Trial of Photodynamic Therapy for Early Gastric Cancer With Photofrin Injection® and YAG‐OPO Laser
RU2146159C1 (ru) Способ фотодинамической терапии злокачественных новообразований
US6586419B1 (en) Phototherapeutic inactivation of ocular viruses
Nyamekye Vascular and other non-tumour applications of photodynamic therapy
RU96107054A (ru) Способ фотодинамической терапии злокачественных новообразований
Lubart et al. Effect of low-energy lasers on the peripheral nervous system and an attempt to explain this phenomenon
RU2229906C2 (ru) Способ волновой терапии

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 352076

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: VERTEPORFIN (VISUDYNE)

Spc suppl protection certif: C200100007

Filing date: 20010126

SPCG Supplementary protection certificate granted

Free format text: VERTEPORFIN (VISUDYNE).

Spc suppl protection certif: C200100007

Filing date: 20010126

Expiry date: 20140719

Effective date: 20040614